Ultragenyx Pharmaceutical (RARE) Institutional Ownership

97.67% of Ultragenyx Pharmaceutical's stock is owned by institutional investors. Learn more on RARE's institutional investor holdings.

Of the 285 institutional investors that purchased Ultragenyx Pharmaceutical's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Norges Bank ($3.21M), Assenagon Asset Management S.A. ($3.16M), Jacobs Levy Equity Management Inc. ($1.86M), Millennium Management LLC ($1.74M), Vestal Point Capital LP ($1.50M), Aberdeen Group plc ($1.15M), and Eagle Health Investments LP ($1.02M).

Institutional investors have bought a total of 29,520,830 shares in the last 24 months. This purchase volume represents approximately $801.80M in transactions.

Of the 101 institutional investors that sold Ultragenyx Pharmaceutical's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Federated Hermes Inc. ($1.56M), Alliancebernstein L.P. ($1.23M), Invesco Ltd. ($1.05M), Assenagon Asset Management S.A. ($964.04K), Deutsche Bank AG ($946.63K), Alyeska Investment Group L.P. ($897.44K), and Farallon Capital Management LLC ($891K).

Institutional investors have sold a total of 17,684,992 shares in the last 24 months. This volume of shares sold represents approximately $501.24M in transactions.